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ABSTRACT
Purpose: This study aimed to investigate the clinical features of recurrent urinary tract 
infection (UTI) in children with vesicoureteral reflux (VUR) and to compare the causative 
uropathogen and antibiotic susceptibility between the first and recurrent UTI episodes.
Methods: We retrospectively reviewed the medical records of children with VUR who had 
recurrent UTI. Group 1 included patients in whom the same pathogen caused the first and 
recurrent UTI episodes. Group 2 included patients in whom different pathogens caused the 
first and recurrent UTI episodes.
Results: During a 13-year study period (2005–2018), 77 children with VUR experienced 
at least one episode of UTI. Among these, 47 patients (61.0%) had recurrent UTI. Of the 
children with recurrent UTI, 19 (40.4%) were in group 1 and 28 (59.6%) were in group 2. 
Escherichia coli was the most commonly isolated uropathogen (n=37; 39.4%) in both episodes 
of recurrent UTIs, followed by Klebsiella pneumoniae (n=18; 19.1%), Enterococcus faecalis (n=14; 
14.9%), and Enterobacter aerogenes (n=7; 7.4%). Although the difference was not significant, the 
rate of resistance to the antibiotics ceftazidime, piperacillin/tazobactam, and trimethoprim-
sulfamethoxazole increased in patients with the second episode of E. coli recurrence in group 
1, and that to cefotaxime, ceftazidime, piperacillin/tazobactam, and meropenem increased in 
children with the second episode of E. aerogenes recurrence in group 1.
Conclusions: When selecting empirical antibiotics for recurrent UTI in children with VUR, 
it is important to consider that the pathogen and antimicrobial susceptibility of the previous 
UTI are not always the same in recurrent UTIs.
Keywords: Urinary tract infections; Vesico-ureteral reflux; Child; Anti-bacterial agents
INTRODUCTION
Vesicoureteral reflux (VUR) predisposes the patients to acute pyelonephritis by facilitating 
bacteria from the bladder to enter the kidney, which can result in renal scarring, renin-
mediated hypertension, or end-stage renal disease.1-4) VUR is present in approximately 30% 
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to 40% of children who had a first episode of urinary tract infection (UTI).5-7) Among patients 
with febrile UTI, children with VUR are 3 times more likely to have a renal injury than those 
without VUR.7) The published Randomized Intervention for VUR trial, a randomized trial of 
trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis for patients with a history of UTI 
and diagnosed VUR, showed a reduction in the recurrence rate of UTIs by approximately 
50%, from 30% in the group not receiving prophylaxis to 15% in that receiving prophylaxis, 
but there was no reduction in the rate of renal scarring with antibiotic prophylaxis.8) 
Therefore, prompt treatment of intercurrent episodes of UTI in patients with VUR is crucial 
in preventing possible renal damage.1)
To date, no precise guideline has been established for the treatment of recurrent UTIs. When 
recurrent UTI occurs in patients with VUR, empirical antibiotic selection tends to be based 
on previous results.1) However, there is little evidence and research on this topic. The recent 
emergence of drug-resistant uropathogens has made it difficult to select empirical antibiotics 
when recurrent UTIs develop in patients with VUR.2,3) The purpose of this study was to investigate 
the clinical features of recurrent UTI in patients with VUR and to compare the causative 
uropathogens and antibiotic susceptibility between the first and recurrent UTI episodes.
MATERIALS AND METHODS
This retrospective observational study was performed in 2 tertiary referral hospitals 
(Severance Children's Hospital and Gangnam Severance Hospital) from April 2005 to 
February 2018. We reviewed the medical charts of all children with VUR aged ≤18 years, who 
experienced at least 1 episode of UTI. The research was approved by the Institutional Review 
Board (No. 4-2018-1086) of the Yonsei University Health System, and the requirements for 
informed consent were waived because of the retrospective nature of the study.
UTI was defined on the basis of the culture of a single pathogen from a catheter urine 
specimen culture with a colony count ≥50,000 or from a clean-catch bag-collected specimen 
culture with ≥100,000 colonies in children with fever (38°C or greater) and pyuria (white blood 
cell count >5 cells/high power field).4) Cases were excluded when 2 pathogens were isolated on 
urine culture. The presence and grade of VUR were determined on voiding cystourethrography 
(VCUG) according to the system proposed by the International Reflux Study Committee.9) Data 
on patient age and sex, grade of VUR, surgical correction, additional urinary tract anomalies, 
and use of prophylactic antibiotics were collected from the medical records.
Any child with ≥2 UTI episodes during the 12-month follow-up period after the initial UTI 
was defined as having had recurrent UTIs.10) Patients with recurrent UTI were also subdivided 
into 2 groups. We compared the uropathogen and clinical features between the first and 
second episodes of UTIs. Group 1 was defined as having the same isolated pathogen in the 
first and second episodes. Group 2 was defined as having different cultured organism in the 
first and second episodes.
In case of group 1 (same strain), antibiotic susceptibility profiles between the first and second 
episodes were compared based on the urine culture results. Sensitivity to an antibiotic was 
defined as the notation of sensitive (S) on the urine culture antibiotic sensitivity results, 
tested using the VITEK2 (bioMeriéux, Marcy-l'Étoile, France) equipment according to the 
Clinical and Laboratory Standards Institute standards.11)
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1. Statistical analysis
Descriptive statistics are expressed for continuous and categorical variables using the 
medians with the interquartile range (IQR) and frequency and percentage, respectively. 
The χ2 test (Fisher's exact test) and the Mann-Whitney U test were used for comparison of 
categorical and continuous variables. Antibiotic sensitivity results between the first and 
second episodes of relapse were compared using the McNemar's test. A P-value of <0.05 was 
considered statistically significant. All analyses were performed using the SAS version 9.3 
statistical package (SAS Institute, Cary, NC, USA).
RESULTS
1. Patient characteristics
During the 13-year study period, 378 patients were screened through diagnostic codes on 
medical records. A total of 301 patients were excluded based on the medical chart review. The 
reasons for exclusion are shown in Fig. 1. As a result, 77 patients were included in the present 
study: 50 boys (64.9%) and 27 girls (35.1%). The median age at diagnosis of the first UTI 
was 6.0 months (IQR, 3.0–14.0 months). UTI was diagnosed in 2 cases by catheterized urine 
culture and in the rest by bag-collected specimen culture.
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Cases excluded based on medical chart review (n=301): 
Patients with insufficient medical records (n=276)
No test results for VUR (n=14)
Cases that were transferred to other hospital after the diagnosis (n=8)
Cases diagnosed with VUR by chance without UTI history (n=2)
Absence of antibiotic susceptibility results (n=1)
UTI recurrence cases after 1 year of initial UTI, 
excluded from the comparison (n=13, 16.9%)
Cases identified through diagnostic code 
on medical records (n=378)
Cases assessed for eligibility (n=77):
Children with VUR who experienced at least one episode of 
UTI between 2005 and 2018





Fig. 1. Flowchart for patient selection. A total of 378 patients were screened through diagnostic codes on medical records from April 1, 2005, to February 28, 
2018. A total of 301 patients were excluded due to inadequate study based on the medical chart review. Group 1 was defined as having the same isolated 
pathogen in the first and second episodes. Group 2 was defined as having different cultured organism in the first and second episodes. 
Abbreviations: VUR, vesicoureteral reflux; UTI, urinary tract infection.
2. Characteristics of the VUR patients with recurrent UTI
Among the 77 patients, 47 (61.0%) had recurrent UTI during 12 months and 17 (22.1%) 
had nonrecurrent UTI. Thirteen (16.9%) were excluded from the comparison because they 
recurred after 1 year of the initial UTI episode. VUR was diagnosed after the first UTI in 40 
patients, after the second UTI in 10 patients, and after the third UTI in 5 patients. Due to the 
hydronephrosis identified in prenatal test, 9 patients were diagnosed with VUR by undergoing 
a VCUG test prior to developing UTI. The median age of first UTI was significantly younger in 
the recurrent UTI patients (5.0 months; IQR, 2.0–8.0) than in the nonrecurrent UTI patients 
(9.0 months; IQR, 6.5–19.0; P<0.001). The proportion of surgical correction after first 
episode of UTI was significantly higher in the nonrecurrent UTI group than in the recurrent 
UTI patients (58.8% vs. 10.6%, P<0.001). However, there were no significant differences in 
sex, laterality and grade of VUR, presence of other tract anomalies, and use of prophylactic 
antibiotics between the recurrent and nonrecurrent UTI groups (Table 1).
Of the 47 children with recurrent UTI, 19 patients (40.4%) were in group 1 and 28 patients 
(59.6%) were in group 2. The median interval between the first and second episodes of UTI 
was 2.0 months (IQR, 1.0–4.0 months). Prophylactic antibiotics were used in 44 (93.6%) of 
recurrent UTI group. Except for 2 patients who used prophylactic antibiotics after the second 
episode of UTI, 42 patients used oral prophylactic antibiotics on average 36.6 days after the 
diagnosis of first episode of UTI. The antibiotics used in group 1 were TMP-SMX (n=9), 2nd 
generation cephalosporin (n=5), 3rd generation cephalosporin (n=1), and aminopenicillins 
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Table 1. Characteristics of VUR patients with or without recurrent UTI







Age of first UTI (mon) 6.0 (3.0–14.0) 5.0 (2.0–8.0) 9.0 (6.5–19.0) <0.001
Sex 0.443
Male 50 (64.9) 35 (74.5) 11 (64.7)
Female 27 (35.1) 12 (25.5) 6 (35.3)
VUR 0.602
Unilateral 44 (57.1) 27 (57.4) 11 (64.7)
Bilateral 33 (42.9) 20 (42.6) 6 (35.3)
VUR grade 0.485
1–2 15 (19.5) 11 (23.4) 2 (11.8)
3–5 62 (80.5) 36 (76.6) 15 (88.2)
Surgical therapy after 1st episode of UTI 
(before 2nd episode of UTI in recurrent 
group)
<0.001
No 60 (77.9) 42 (89.4) 7 (41.2)
Yes 17 (22.1) 5 (10.6) 10 (58.8)
Concomitant urinary tract abnormalities† 0.777
No 36 (46.8) 23 (48.9) 9 (52.9)
Yes 41 (53.2) 24 (51.1) 8 (47.1)
Prophylactic antibiotics 1.000
No 4 (5.2) 3 (6.4) 1 (5.9)
Yes 73 (94.8) 44 (93.6) 16 (94.1)
Data are expressed as number (%) or the medians with the interquartile range.
Abbreviations: UTI, urinary tract infection; VUR, vesicoureteral reflux.
*Thirteen were excluded from the comparison because they recurred after 1 year of the initial UTI episode; 
†Concomitant urinary tract abnormalities in recurrent UTI group included posterior urethral valve (n=5), 
ureterovesical junction anomaly (n=4), dysplastic kidney (n=3), vesico-ureteral diverticulum (n=3), renal duplex 
system (n=2), bladder outlet stenosis (n=2), hypospadias (n=1), autosomal recessive polycystic kidney disease 
(n=1), cloacal anomaly (n=1), recto-urethral fistula (n=1), and vesico-urachal remnant (n=1). Concomitant urinary 
tract abnormalities in nonrecurrent UTI group included bulbous urethra ring (n=2), posterior urethral valve (n=1), 
ureterovesical junction anomaly (n=1), dysplastic kidney (n=1), vesico-ureteral diverticulum (n=1), hypospadias 
(n=1), and cryptorchidism (n=1).
(n=2). The antibiotics used in group 2 were TMP-SMX (n=19), 2nd generation cephalosporin 
(n=5), and 3rd generation cephalosporin (n=1). The proportion of male patients were 
significantly higher in group 2 than in group 1 (85.7% vs. 57.9%, P=0.045). However, there 
were no significant differences in the other variables between the 2 groups (Table 2).
3. Etiology of the first and second episodes of UTI
Urine culture results of both the first and second episodes of recurrent UTIs are shown in 
Table 3. Escherichia coli was the most commonly isolated uropathogen (n=37, 39.4%), followed 
by Klebsiella pneumoniae (n=18, 19.1%), Enterococcus faecalis (n=14, 14.9%), Enterobacter aerogenes 
(n=7, 7.4%), and Pseudomonas aeruginosa (n=4, 4.3%).
Twenty-seven (57.4% of 47) of the children with VUR with recurrent UTI experienced 
recurrence of UTI more than once during the 12-month follow-up period after the initial UTI. 
Twenty (42.6% of 47) patients experienced a single episode of recurrence. The uropathogens 
involved in each recurrent episode in children with VUR are shown in Supplementary Table 1.
E. coli was the most common pathogen (n=20, 52.6%) in group 1 (Table 3). In the cases with  
E. coli recurrence in group 1, antibiotic resistance rate to ceftazidime, piperacillin/tazobactam,  
and TMP-SMX increased in the second episode but was not statistically significant. In 
addition, antibiotic resistance rate to cefotaxime, ceftazidime, piperacillin/tazobactam, and 
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Table 2. Characteristics of patients with recurrent UTI
Variable Total (n=47) Group 1 (n=19) Group 2 (n=28) P-value
Age at first UTI (mon) 5.0 (2.0–8.0) 5.0 (3.0–8.0) 4.5 (2.0–7.5) 0.395
Sex 0.045
Male 35 (74.5) 11 (57.9) 24 (85.7)
Female 12 (25.5) 8 (42.1) 4 (14.3)
VUR 0.514
Bilateral 27 (57.4) 12 (63.2) 15 (53.6)
Unilateral 20 (42.6) 7 (36.8) 13 (46.4)
VUR grade 0.276
1–2 11 (23.4) 6 (31.6) 5 (17.9)
3–5 36 (76.6) 13 (68.4) 23 (82.1)
Interval between the first and second 
episodes of UTI (mon)
2.0 (1.0–4.0) 2.0 (1.0–4.0) 2.0 (1.0–4.75) 0.796
Surgical therapy after 1st episode of UTI 
(before 2nd episode of UTI)
0.051
No 42 (89.4) 19 (100) 23 (82.1)
Yes 5 (10.6) 0 (0) 5 (17.9)
Concomitant urinary tract abnormalities* 0.859
No 23 (48.9) 9 (47.4) 14 (50.0)
Yes 24 (51.1) 10 (52.6) 14 (50.0)
Prophylactic antibiotics 0.557
No 3 (6.4) 2 (10.5) 1 (3.6)
Yes 44 (93.6) 17 (89.5) 27 (96.4)
Data are expressed as number (%) or the medians with the interquartile range.
Group 1 was defined as having the same cultured pathogen in the first and recurrent episodes. Group 2 was 
defined as having different cultured pathogens between the first and recurrent episodes.
Abbreviations: UTI, urinary tract infection; VUR, vesicoureteral reflux.
*Concomitant urinary tract abnormalities in group 1 included posterior urethral valve (n=4), ureterovesical 
junction anomaly (n=1), renal duplex system (n=1), hypospadias (n=1), cloacal anomaly (n=1), vesico-urachal 
remnant (n=1) and recto-urethral fistula (n=1). Concomitant urinary tract abnormalities in group 2 included 
ureterovesical junction anomaly (n=3), dysplastic kidney (n=3), vesico-ureteral diverticulum (n=3), bladder outlet 
stenosis (n=2), posterior urethral valve (n=1), renal duplex system (n=1), and autosomal recessive polycystic 
kidney disease (n=1).
meropenem increased in patients with second episode of E. aerogenes recurrence in group 1, 
although the difference was not significant (Table 4).
DISCUSSION
This study showed that the uropathogen between the previous and recurrent episodes may 
differ in cases of recurrent UTI in children with VUR. Furthermore, we found a difference 
in antibiotic susceptibility even between the first and second episodes of UTI by the same 
pathogen in group 1, but the difference was not statistically significant.
In our study, there was a male predominance in children with VUR. These findings are in 
contrast to the results of Chand et al.,12) who reported that females were twice as likely to have 
VUR as males. However, our results correspond with the result of an earlier study in Korea, 
which reported that among the children diagnosed with VUR, 91 (61.9%) were boys and 56 
(38.1%) were girls.13) In addition, there are several reports stating that the sex difference in 
children with VUR is lower in countries where circumcision is not routinely performed.14,15) 
Further research is needed to determine if circumcision during infancy affects the sex 
difference in VUR.
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Table 3. Urine culture results in recurrent urinary tract infection episodes
Strains isolated from urine culture Total episodes First episode Second episode
Escherichia coli 37 (39.4) 17 (18.1) 20 (21.3)
Klebsiella pneumoniae 18 (19.1) 7 (7.4) 11 (11.7)
Enterococcus faecalis 14 (14.9) 7 (7.4) 7 (7.4)
Enterobacter aerogenes 7 (7.4) 4 (4.3) 3 (3.2)
Pseudomonas aeruginosa 4 (4.3) 3 (3.2) 1 (1.1)
Enterobacter cloacae 3 (3.2) 3 (3.2) 0 (0.0)
Citrobacter freundii 2 (2.1) 1 (1.1) 1 (1.1)
Klebsiella oxytoca 2 (2.1) 0 (0.0) 2 (2.1)
Enterococcus faecium 2 (2.1) 2 (2.1) 0 (0.0)
Other* 5 (5.3) 3 (3.2) 2 (2.1)
Total 94 (100) 47 (50) 47 (50)
Group 1
E. coli 20 (52.6) 10 (26.3) 10 (26.3)
K. pneumoniae 10 (26.3) 5 (13.2) 5 (13.2)
E. aerogenes 4 (10.5) 2 (5.3) 2 (5.3)
E. faecalis 2 (5.3) 1 (2.6) 1 (2.6)
P. aeruginosa 2 (5.3) 1 (2.6) 1 (2.6)
Total 38 (100) 19 (50) 19 (50)
Group 2
E. coli 17 (30.4) 7 (12.5) 10 (17.9)
E. faecalis 12 (21.4) 6 (10.7) 6 (10.7)
K. pneumoniae 8 (14.3) 2 (3.6) 6 (10.7)
E. aerogenes 3 (5.4) 2 (3.6) 1 (1.8)
E. cloacae 3 (5.4) 3 (5.4) 0 (0.0)
P. aeruginosa 2 (3.6) 2 (3.6) 0 (0.0)
C. freundii 2 (3.6) 1 (1.8) 1 (1.8)
K. oxytoca 2 (3.6) 0 (0.0) 2 (3.6)
E. faecium 2 (3.6) 2 (3.6) 0 (0.0)
Other* 5 (8.9) 3 (5.4) 2 (3.6)
Total 56 (100) 28 (50) 28 (50)
Data are expressed as number (%).
Group 1 was defined as having the same cultured pathogen in the first and recurrent episodes. Group 2 was 
defined as having different cultured pathogens between the first and recurrent episodes.
*Acinetovactoer pittii, Enterobacter amnigenus, Klebsiella planticola, Morganella morganii, Proteus vulgaris.
The age at the diagnosis of the first UTI in the present study was significantly younger in the 
recurrent UTI patients than in the nonrecurrent patients. These results correspond with those 
of earlier studies which reported that the younger the first UTI then the higher the risk is for 
recurrent UTIs in children with VUR.16,17) These findings are seen even in children with normal 
urinary tract systems without VUR. Shim et al.18) have shown in a group of 190 children less 
than 12 months of age with normal urinary systems that the recurrence rate in infants less 
than 6 months of age was 25.0%, which was significantly higher than the 5.3% in older infants 
(P=0.008). Therefore, these results suggest that clinicians evaluating fever in young infants 
with a history of UTI should maintain a high index of suspicion for recurrent UTI.
Our results showed that 57.8% of recurrent UTI cases in children with VUR were caused by 
pathogens different from the first episode of UTI, which are in agreement with those of Wu 
et al.,19) who reported that 64.7% of recurrent UTI patients with VUR developed reinfection. 
UTIs are caused primarily by bacteria in the gastrointestinal and vaginal tracts. Antibiotics 
used in the first episode of UTI may cause changes in the composition of colonic bacteria, 
and as a result, the second episode of UTI could be caused by a new bacterial strain in the 
altered gut microbiota. Numerous studies that have confirmed that antibiotics alter the 
composition and functions of the human intestinal microbiota support our hypothesis.20,21)
In this study, boys had a greater rate of group 2, whereas girls had a greater rate of group 1. 
This is probably due to the differences in the anatomical structures of the genitourinary tract 
between the 2 sexes. The vaginal tract could act as the local reservoir of the same bacterial 
strain when UTI recurs. Several studies have found that most strains obtained from patients 
with relapse infections were biofilm producers in vitro.22-24) Uropathogens can persist within 
the vaginal tissue by biofilm formation and serve as a source of relapse UTIs in females. 
Future research on the etiology differences of UTI in males and females is needed. Several 
studies have demonstrated, using pulsed field gel electrophoresis (PFGE), that 50% to 68% 
of strains causing relapse symptomatic UTI were similar to the index strains, suggesting that 
most relapsed UTIs are endogenous relapses rather than reinfections by new strains.15,25-28) 
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Table 4. Urine culture results and the antimicrobials susceptibility in group 1
Pathogens No. of 
strain 
(%)
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Antibiotic susceptibility results that differ from the first episode are shaded in the second episode with 2 levels of intensities: lighter shade, increase in 
susceptibility percentage; darker shade, decrease in susceptibility percentage.
Group 1 was defined as having the same cultured pathogen in the first and recurrent episodes.
Abbreviations: UTI, urinary tract infection; AMK, amikacin; AMP, ampicillin; CIP, ciprofloxacin; Ceftaz, ceftazidime; CTX, cefotaxime; Gent, gentamicin; Levo, 
levofloxacin; LZD, linezolid; MER, meropenem; OXA, oxacillin; PIP-TZ, piperacillin/tazobactam; TMP-SMX, trimethoprim-sulfamethoxazole; Vanco, vancomycin.
In relapses of both E. coli and K. pneumoniae in group 1 of this study, the antibiotic susceptibility 
results of the first and second episodes were slightly different but not statistically significant. 
These findings suggest that even in relapses by endogenous strains, antimicrobial susceptibility 
patterns at recurrence may be different from those in the previous episode. Therefore, empirical 
antibiotics should be selected according to the treatment effects in association with clinical 
features. Further studies on the antibiotic susceptibility of relapse strains are needed.
This study has some limitations. First, this was a retrospective study with a small sample 
size and was performed at 2 tertiary referral hospitals. Owing to the nature of the referral 
hospitals, VUR had already been diagnosed at other hospitals, leading to an increased 
exclusion of potential subjects. Further multicenter studies are required to validate the study 
results. Second, we did not evaluate the association between the appropriateness of the 
empirical antimicrobial regimen and the clinical outcomes according to the antimicrobial 
susceptibility test results in each episode of UTI. Third, in group 1, we did not perform 
further tests such as PFGE; thus, it was unclear whether the bacterial strain cultured in the 
second episode was similar to that in the first episode.
The major strength of this study is that to our knowledge, it is the first study to compare 
the causative uropathogens between the first and second episode of UTI in children with 
VUR. Our study can make a significant contribution to the literature because it shows 
the importance of carefully selecting antibiotics, considering that the pathogen and the 
antibiotic susceptibility results between the first and second episodes may differ. This can 
lead to changes in policies in the treatment of recurrent UTI in patients with VUR.
In conclusion, it is difficult to clinically determine whether the recurrence is caused by the 
same or different species as the previous infection in case of recurrent UTI in children with 
VUR. Even in recurrence caused by the same pathogen in the first episode, the antibiotic 
susceptibility results between the first and second episodes were slightly different. Therefore, 
when selecting empirical antibiotics in recurrent UTI, it should be taken into account that the 
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요약
목적: 본 연구의 목적은 방광 요관 역류(vesicoureteral reflux) 환아에서 재발성 요로감염의 임상양상을 조사하고, 첫 번째 및 
재발성 요로감염 간의 원인균과 항생제 감수성 결과를 비교하는 것이다.
방법: 방관 요관 역류로 진단된 소아 환자 중에서 요로감염이 발생한 환자의 의무기록을 후향적으로 검토하였다. 첫 번째와 
두 번째 요로감염 건에서 같은 균종이 동정된 경우를 1군으로, 다른 균종이 동정된 경우를 2군으로 분류하여 분석하였다.
결과: 2005년 4월부터 2018년 2월까지 총 13년 간의 연구 기간 동안, 총 77명의 방관 요관 역류 환아가 적어도 한 번 이상의 
요로감염을 경험하였다. 이 중 47명의 환자(61.0%)가 재발성 요로감염 소견을 보였다. 재발성 요로감염 환자 중에서 1군은 19명
(40.4%)이었고, 2군은 28명(59.6%)이었다. Escherichia coli (n=37, 39.4%)는 재발성 요로감염 환자의 첫 번째 및 두 번째 요로감염 
건에서 가장 흔하게 분리된 원인균이었고, 그 다음으로는 Klebsiella pneumoniae (n=18, 19.1%), Enterococcus faecalis (n=14, 
14.9%), Enterobacter aerogenes (n=7, 7.4%), 및 Pseudomonas aeruginosa (n=4, 4.3%) 순이었다. 비록 통계적 차이는 없었지만, 
E. coli에 의한 재발 시, 같은 균에 의한 재발 임에도 ceftazidime, piperacillin/tazobactam과 trimethoprim-sulfamethoxazole에 
대한 항생제 내성의 비율이 첫 번째보다 두 번째 감염에서 증가하였고, E. aerogenes에 의한 재발에서도 cefotaxime, ceftazidime, 
piperacillin/tazobactam 및 meropenem에 대한 항생제 내성의 비율이 첫 번째보다 두 번째 감염에서 증가하였다.
결론: 방관 요관 역류 환아의 재발성 요로감염에서 경험적 항생제를 선택할 때, 이전 감염의 병원균 및 항균제 감수성 결과가 
재발 시에 항상 동일하지는 않다는 점을 염두에 두어야 한다.
